

بسم الله الرحمن الرحيم

 $\infty\infty\infty$

تم رفع هذه الرسالة بواسطة / حسام الدين محمد مغربي

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى مسئولية عن محتوى هذه الرسالة.

AIN SHAMS UNIVERSITY

Since 1992

Propries 1992

ملاحظات: لا يوجد





Cardiac Follow up of Pediatric Patients Presented with Covid-19 Cardiovascular Affection

Thesis

Submitted for Partial Fulfillment of Master's Degree in Pediatrics

 $\mathcal{B}y$

Hager Mostafa Belal Hassan

M.B., B.Ch., Faculty of Medicine, Ain Shams University (2017).

Under Supervision of

Prof. Dr. Mona Mostafa El-Ganzoury

Professor of Pediatrics Faculty of Medicine, Ain Shams University

Prof. Dr. Waleed Mohamed El Guindy

Professor of Pediatrics Faculty of Medicine, Ain Shams University

Dr. Nora Hussein Mahmoud El-Samman

Lecturer of Pediatrics Faculty of Medicine, Ain Shams University

Faculty of Medicine
Ain Shams University
2022



سورة البقرة الآية: ٣٢

Acknowledgments

First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.

I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Mona Mostafa El-Ganzoury**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.

Special thanks are due to **Prof. Dr. Waleed**Mohamed El Guindy, Professor of Pediatrics, Faculty of

Medicine, Ain Shams University, for his sincere efforts,

fruitful encouragement.

I am deeply thankful to **Dr. Mora Hussein**Mahmoud El-Samman, Lecturer of Pediatrics, Faculty of

Medicine, Ain Shams University, for his great help,
outstanding support, active participation and guidance.

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Hager Mostafa Belal Hassan

Tist of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	vii
Introduction	1
Aim of the Work	2
Review of Literature	
Chapter 1: COVID 19	3
Chapter 2: Multiinflammatory Syndrome in C	hildren 28
Chapter 3: Covid-19 Carditis	44
Patients and Methods	57
Results	60
Discussion	
Summary	113
Conclusion	
Recommendations	116
References	117
Arabic Summary	

Tist of Tables

Table No	o. Title Page No.	
Table 1:	Clinical symptoms of patients with 2019-nCoV infection:	.13
Table 2:	Pediatric doses of used medications	.23
Table 3:	Definition of MIS-C	.29
Table 4:	Comparison of clinical and laboratory features of MIS-C with KD, KDSS and TSS	.35
Table 5:	Prevalence of Different Cardiac Signs and Symptoms in Patients With Multisystem Inflammatory Syndrome in Children (MIS-C)	.47
Table 6:	Demographic data and anthropometric measures of the studied patients:	.60
Table 7:	Vital data of the studied patients:	.62
Table 8:	Shows the presentation of symptoms and signs among our patients:	.63
Table 9:	Shows medications used in treatment of our patients:	.65
Table 10:	Shows COVID-19 status in studied patients:	.67
Table 11:	Shows fate of patients admitted to our center:	.68
Table 12:	Initial and follow up for laboratory data of the studied patients:	.69
Table 13:	Initial and follow up ECG parameters among studied patients:	.74
Table 14:	Comparison of ECHO parameters initially and during follow up at 1, 6 weeks, 3 months;	.77
Table 15:	Comparison of coronary arteries dimensions between initially and durind follow up:	.80

Tist of Tables cont...

Table No	. Title	Page No.
Table 16:	Describes valvular cardiac affect during the follow up at 1,6 weeks	•
Table 17:	Correlation between ECHO clinical, laboratory, ECG parame	1
Table 18:	Correlation between ECHO clinical, laboratory, ECG parame	-
Table 19:	Relation between rash as cli ECHO parameters initial and at	<u>-</u>
Table 20:	Relation between diarrhea as cl ECHO parameters initial and at	<u> </u>

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Pathogenesis of SARS-CoV-2 inf	ection5
Figure 2:	Typical patterns of COVID-19 a Ground glass shadows (early sta	0 0
Figure 3:	Scheme of COVID-19 managem and adolescents	
Figure 4:	Breast feeding and covid-19	22
Figure 5:	Suggested algorithm for risk str considering thromboprophylaxi with COVID-19 infection	s for children
Figure 6:	Infographic showing CDC crediagnosis of MIS-C	
Figure 7:	Pathogenesis of MIS-C	32
Figure 8:	MIS-C management based on ris	sk criteria42
Figure 9:	MIS-C therapeutics	43
Figure 10:	T wave inverstion in all cardiac	walls50
Figure 11:	Ventricular dysfunstion	51
Figure 12:	Coronary dilation and aneurysm	as51
Figure 13:	Comparison between Small and	Dilated LV52
Figure 14:	Algorithm for clinical as management of carditis in MIS-	- -
Figure 15:	Dilated RCA	59
Figure 16:	Sex distribution among the stud	ied patients61
Figure 17:	Shows the presentation of symp among our patients	•
Figure 18:	Shows medications used in trepatients	

Tist of Figures cont...

Fig. No.	Title	Page No.
Figure 19:	Shows COVID-19 status in stu	died patients67
Figure 20:	Shows fate of patients admitted	d to our center68
Figure 21:	Shows that the major improvement of CRP at 1 week	<u> </u>
Figure 22:	Shows that major change and D dimer at 1 week follow up	_
Figure 23:	Showed that the major chang and return to normal was bet follow up	ween 1, 6 weeks
Figure 24:	This figure showed that me troponin level and return between 1,6 weeks follow up	to normal was
Figure 25:	This figure showed that me CKMB level and return to me months follow up	ormal was at 3
Figure 26:	Show improvement of HR patients during follow up	_
Figure 27:	Initial and follow up median of among studied patients	
Figure 28:	Initial and follow up median or among studied patients	
Figure 29:	Comparison of percentage of p dilated LV, initially 36.4% had improved at 1 week follow up b	l dilated LV who
Figure 30:	Shows improvement of media RCA during the follow up	
Figure 31:	Shows improvement of median during the follow up	

Tist of Figures cont...

Fig. No.	Title	Page No.
Figure 32:	Shows comparison of RCA diam Z score among studied patients and during follow up at 1,6 wee patients (72.7%) had average patients (6.1%) had small aneu (21,2%) had dilated RCA diame 0.91 with range (-1.58–3)	s between initial ks, 3 months, 24 e coronaries, 2 arysm,7 patients eter with median
Figure 33:	Shows comparison of LCA diagram to Z score among studied partial and during follow up a months	atients between at 1,6 weeks, 3
Figure 34:	Shows comparison of percent patients presented with PR b and during follow up at 1,6 week	etween initially
Figure 35:	Shows comparison of percent patients presented with AR b and during follow up at 1,6 week	etween initially
Figure 36:	Shows comparison of percent patients presented with MR b and during follow up at 1,6 week	etween initially
Figure 37:	Shows comparison of percent patients presented with TR b and during follow up at 1,6 week	etween initially
Figure 38:	Shows that there is negate between FS, CKMB with p when CKMB decreased, FS inc.	value 0.033, As
Figure 39:	Shows that there is positive between Zscore of LVES significant P value of 0.027 a increased, ZSCORE OF LVEST	D,CKMB with as when CKMB

Tist of Figures cont...

Fig. No.	Title	Page No.
Figure 40:	Shows that there is positive between CRP,Z score of RCA at up with significant P value of 0. CRP increased, Zscore of RCA inc	1 week follow .008,,as when
Figure 41:	Shows that there is positive between CRP, Zscore of LCA at up with significant P value 0.05, increased, Zscore of LCA increase	1 week follow as when CRP
Figure 42:	Shows that there is positive between D Dimer, Zscore of LVEI follow up with significant P value when D Dimer increased, Zscor increased	DD at 1 week ne of 0.049,as re of LVEDD
Figure 43:	Shows that there is positive between D Dimer, Zscore of LVES follow up with significant P vs when D Dimer increased, Zscor increased	SD at 1 week alue 0.008,as re of LVESD

Tist of Abbreviations

Abb.	Full term
ACE	Angietengin conventing engryme
	Angiotensin converting enzyme
	Angiotensin-converting enzyme 2
	Antibody-dependent enhancement
	Aortic regurgitation
	Acute respiratory distress syndrome
BMI	·
	Brain natriuretic peptide
	B-type natriuretic peptide
	Case fatality rate
	Comprehensive metabolic profile
CRP	C-reactive protein
CT	Computed tomography
CVL	Central venous catheter
DBP	Diastolic blood pressure
ECG	Electrocardiogram
ECHO	Echocardiography
ECMO	Extra Corporeal Membrane Oxygenation
EF	Ejection fraction
ESR	Erythrocyte sedimentation rate
FS	Fractional shortening
	Granulocyte-colony stimulating factor
HcoV	Human coronavirus
HLH	Hemophagocytic lymphohistiocytosis
HR	
ICU	Intensive care unit
IFN	Interferon
IL	Interleukin
IP10	Interferon-Inducible Protein 10

Tist of Abbreviations cont...

Abb.	Full term
IV	Intravenous
IVF	
	.Intravenous immune globulin
KD	_
KDSS	.Kawasaki Disease Shock Syndrome
	.Left coronary artery
LDH	.Lactate dehydrogenase
LV	.Left ventricular
MAS	.Macrophage activation syndrome
MAS	.Macrophage Activation Syndrome
MCP1A	.Monocyte Chemoattractant Protein-1
MERS-CoV	.Middle Eastern respiratory syndrome coronavirus
MIS-C	.Multisystem inflammatory syndrome in children
MR	.Mitral regurgitation
MRI	.Magnetic resonance imaging
NAAT	.Nucleic acid amplification test
NK	.Natural killer
NT-proBNP	.N-terminal pro–B-type natriuretic peptide
O2	.Oxygen
PARDS	.Pediatric Acute Respiratory Distress Syndrome
PE	.Pericardial effusion
PICU	.Pediatric intensive care unit
PR	.Pulmonary regurgitation
proBNP	.Pro-B-type natriuretic peptide
PT	.Prothrombintime
PTT	.Partial thromboplastin time

Tist of Abbreviations cont...

Abb.	Full term
QTc	Corrected QT
=	Renin-angiotensin system
	Right coronary artery
RR	
	Severe acute respiratory syndrome coronavirus
SARS-HcoV	Severe Acute Respiratory Syndrome human coronavirus
SBP	Systolic blood pressure
SHLH	Secondary hemophagocytic lymphohistiocytosis
So2	Oxygen saturation
TLR	Toll-Like Receptor
TNF	Tumor necrosis factor
TNF-β	Tumor necrosis factor β
TR	Tricuspid regurgitation
TSS	Toxic shock syndrome
TTE	Transthoracic echocardiography
ULN	Upper limit of normal.
VIS	Vasoactive-inotropic score

Introduction

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection has rapidly spread worldwide since it was first identified in China in late 2019, with subsequent epicenters being recognized in Europe and the U.S. Previous reports of SARS-CoV-2 infection indicated that young children were disproportionately spared from infection (CDC, 2020; Parri et al., 2020).

Although it remains unclear if this is due to a lack of detection because of predominantly asymptomatic or mild disease in this age group. In the latter half of April 2020, a novel syndrome in children and adolescents termed "multisystem inflammatory syndrome in children" (MIS-C) with likely relation to SARS-CoV-2 infection was first described. Initial reports surfaced in the UK (*Riphagen et al., 2020*) and Italy (*Verdoni et al., 2020*), followed by New York and other parts of the U.S. Preliminary accounts of the features of this syndrome resemble those of known entities such as Kawasaki Disease (KD), toxic shock syndrome (TSS), and secondary hemophagocytic lymphohistiocytosis (SHLH)/ macrophage activation syndrome (MAS).